The short version of Mass spectrometry fits in a sentence. The long version — which is the one that helps — is below.
This page was last updated on 2026-02-15 and is reviewed periodically as new material appears.
Lyophilized material is generally reported as stable for extended periods when kept cold, dry, and protected from light. In solution, the main degradation routes for a peptide of this type are hydrolysis of peptide bonds and aggregation. The sequence contains no cysteine, so disulfide-driven oxidation is not a primary concern, though methionine and tryptophan are also absent. Stability depends on pH, buffer composition, and concentration, with acidic conditions often reported as more favorable than neutral or alkaline ones. Repeated freeze-thaw cycles can promote aggregation, and how fast degradation proceeds at room temperature in specific formulations remains an open question.
Handling practice centers on limiting moisture, heat, and mechanical stress. Powder is typically allowed to reach room temperature before opening so that condensation does not form on the contents, and solutions are prepared with sterile or low-particulate water. Peptides can adsorb to certain plastics and membrane filters, so container and filter material is sometimes specified to reduce losses at low concentrations. Working aliquots are usually frozen separately rather than sampled repeatedly from one stock. Recording lot number, preparation date, and storage conditions supports later comparison between experiments.
BPC-157 is a synthetic peptide composed of fifteen amino acids. Its sequence corresponds to part of a protein found in human gastric juice, which is the origin of the "body protection compound" label. In laboratory work the material is treated as a defined research chemical rather than a finished product. Published research has centered on animal models, and the peptide is not an approved medicine in most countries.
The peptide was first described in the early 1990s by a group studying gastric secretions and tissue repair. Its fifteen-residue chain is usually written as GEPPPGKPADDAGLV in single-letter code. The free peptide has the formula C62H98N16O22 and a theoretical mass near 1419.5 daltons. These identifiers are established chemical facts that can be checked against standard peptide databases. There is no ambiguity about the primary structure.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white powder | Typical lyophilized form |
| Solubility | Freely soluble in water | Also dissolves in common polar solvents |
| Storage temperature | Minus 20 degrees Celsius or lower | Applies to dry powder, desiccated and dark |
| Typical analytical methods | Reversed-phase HPLC and mass spectrometry | Used together for purity and identity |
| Primary degradation route | Hydrolysis and aggregation | No cysteine present, so disulfide formation is unlikely |
Published work on BPC-157 spans several decades and covers a wide range of experimental models. Much of the early literature reports outcomes in animal studies involving induced injury to the gastrointestinal tract, tendons, and other tissues. The volume of preclinical reports is large, while controlled human trials remain scarce. This imbalance is a recurring point of discussion, because animal findings do not automatically translate into human effects. Reviews often note that study designs differ substantially across laboratories.
Interest in the peptide has grown through online communities that discuss self-administered use, which sits outside formal research settings. Regulatory status varies by country, and in many jurisdictions the compound is not approved as a therapeutic product. Questions about optimal routes of administration, long-term effects, and dose-response relationships remain open. Published pharmacokinetic data in humans are limited, and much of what circulates in popular discussion is extrapolated from animal work rather than measured directly in people.
BPC-157 is a synthetic peptide built from fifteen amino acids, referred to in the literature as a pentadecapeptide. Its sequence was derived from a larger protein found in human gastric juice, commonly called body protection compound. Researchers first described the fragment in the early 1990s and named it after the parent protein plus a numeric identifier. The peptide does not correspond to a single marketed medicine; it is primarily a laboratory research material. Suppliers distribute it as a lyophilized powder intended for experimental use.
BPC-157 is a synthetic peptide of fifteen amino acids, written as GEPPPGKPADDAGLV, whose sequence matches part of a larger protein identified in human gastric juice. That parent protein was described in stomach-secretion research, and the fifteen-residue fragment was named body protection compound, which gives the peptide its common label. Material used in experiments is produced by solid-phase peptide synthesis rather than extracted from tissue. The reported molecular weight is about 1419 daltons, and the chain contains several proline residues, a feature that appears in discussions of its resistance to enzymatic breakdown.
Most published findings come from rodent models, where the peptide has been examined in wound-healing, gastrointestinal-lesion, tendon, and vascular-injury preparations. A smaller number of early human studies have been reported, chiefly in inflammatory bowel conditions, but the public record is short and has not led to marketing approval in the United States or the European Union. Reviewers therefore classify the compound as investigational, and whether animal results carry over to people remains an open question rather than a settled one.
Outside laboratory supply channels, the peptide is sold as a research chemical, a category that carries no requirement to demonstrate purity, identity, or freedom from contamination. Because it is not an approved medicine, products labeled BPC-157 sit in a regulatory gap in many countries, and actual content may differ from the label. Sports organizations list it among prohibited substances, so its presence in an athlete's sample can produce a doping finding regardless of how the material was obtained.
The sequence places several glycine and proline residues near the middle, which may influence how the chain folds in solution. The peptide is linear rather than cyclic, and it carries no disulfide bridges. Commercial material is commonly supplied as the acetate salt, although the free base and other counterion forms also appear. Because the term BPC-157 refers to a specific sequence, samples with slight sequence variants are chemically different substances. Published work generally treats the fifteen-residue sequence as the defining structure.
Physical descriptions in supplier documents and papers usually list the compound as a white to off-white powder. It dissolves readily in water and in common aqueous buffers, and solutions are often prepared fresh before an experiment. Molecular mass near 1419 daltons helps verify identity during mass spectrometry. The powder is somewhat hygroscopic, so moisture exposure can alter the measured mass of a sample. Purity is typically reported as a percentage from chromatographic analysis.
BPC-157 is a synthetic fifteen-amino-acid peptide whose sequence is GEPPPGKPADDAGLV. Its name derives from the phrase body protection compound, a term applied to a protein fraction originally detected in human gastric juice. The short peptide is not that full protein; it corresponds to a stable fragment of the larger molecule. Researchers frequently describe it as a pentadecapeptide because it contains exactly fifteen residues. Its neutral molecular mass is approximately 1419 daltons.
== Notable achievements and awards == In 1996, Kessler became a member of the Bavarian Academy of Sciences and Humanities, one of the eight state academies in Germany. In 2002, he was elected to membership of the Academy of Sciences Leopoldina, the national academy of Germany.
=== Therapeutic resistance and tumor aggressiveness === In pancreatic ductal adenocarcinoma (PDAC), ITGA1 promotes tumor progression by regulating tumor cell survival, extracellular matrix (ECM) signaling, and chemotherapy resistance. ITGA1-mediated signaling enhances epithelial-mesenchymal transition (EMT), metastatic potential, and resistance to gemcitabine, a commonly used chemotherapeutic agent for PDAC. Inhibition of ITGA1 increases sensitivity to chemotherapy, suggesting that targeting ITGA1-dependent ECM signaling may improve therapeutic responses in aggressive pancreatic cancer. In PDAC, ITGA1 marks and functionally regulates AIDH1-high pancreatic cancer cells with stem-like properties. These ITGA1-positive tumor-initiating cells lead to metastasis, therapy resistance, as well as poor prognosis. Inhibition of ITGA1 reduces the tumor-initiating ability of these cells, suggesting that ITGA1 may represent a strategy for targeting resistant cancer populations in PDAC.
===== Type 2B ===== This is a "gain of function" defect. The ability of the qualitatively defective VWF to bind to glycoprotein Ib (GPIb) receptor on the platelet membrane is abnormally enhanced, leading to its spontaneous binding to platelets and subsequent rapid clearance of the bound platelets and of the large VWF multimers. Thrombocytopenia may occur. Large VWF multimers are reduced or absent from the circulation. The ristocetin cofactor activity is low when the patient's platelet-poor plasma is assayed against formalin-fixed, normal donor platelets. However, when the assay is performed with the patient's own platelets (platelet-rich plasma), a lower-than-normal amount of ristocetin causes aggregation to occur. This is due to the large VWF multimers remaining bound to the patient's platelets. Patients with this subtype are unable to use desmopressin as a treatment for bleeding, because it can lead to unwanted platelet aggregation and aggravation of thrombocytopenia.
Sources: en.wikipedia.org
These rubidium standards are often used with GNSS to produce a "primary frequency standard" that has greater accuracy and is less expensive than caesium standards. Such rubidium standards are often mass-produced for the telecommunications industry. Other potential or current uses of rubidium include a working fluid in vapor turbines, as a getter in vacuum tubes, and as a photocell component. Rubidium is also used as an ingredient in special types of glass, in the production of superoxide by burning in oxygen, in the study of potassium ion channels in biology, and as the vapor in atomic magnetometers. In particular, 87Rb is used with other alkali metals in the development of spin-exchange relaxation-free (SERF) magnetometers. Rubidium-82 is used for positron emission tomography. Rubidium is very similar to potassium, and tissue with high potassium content will also accumulate the radioactive rubidium. One of the main uses is myocardial perfusion imaging. As a result of changes in the blood–brain barrier in brain tumors, rubidium collects more in brain tumors than normal brain tissue, allowing the use of radioisotope rubidium-82 in nuclear medicine to locate and image brain tumors. Rubidium-82 has a very short half-life of 76 seconds, and the production from decay of strontium-82 must be done close to the patient. Rubidium was tested for the influence on bipolar disorder and depression. Dialysis patients suffering from depression show a depletion in rubidium, and therefore a supplementation may help during depression.
Disagreements arose, because the brigand wanted to assault Platì and take revenge on the local liberals, unlike Borjes, who eventually gave in. The unsuccessful assault took place on September 17. The brigands and legitimists were repelled by the National Guards and a regular army unit. This failure soon ended their collaboration. On October 20 Borjes traveled to Basilicata to join his forces with those of Carmine Crocco. They achieved successes, but not the final objective, as the brigand leader refused to turn his men into a regular army. Noting the failure of the plan, the Catalan general attempted to travel to Rome to report to the Bourbon ruler. He was captured in Tagliacozzo and shot on 8 December 1861. Borjes' failure did not end brigandage, which continued with greater virulence. For this reason, the first Minghetti government promulgated the Pica law on 15 August 1863. It was a regulation that suspended constitutional guarantees for the southern provinces and imposed a state of siege. It delivered brigands to military tribunals, without appeal or defense. In Calabria the law was applied in Citeriore and Calabria Ulteriore Seconda, while the Reggio area, as was the area around Naples and part of Apulia were exempted. The Pica law remained in force until 31 December 1865, and contributed to eradicating banditry, albeit with repressive methods and without resolving the southern territories' social and economic problems. An underlying issue was latifundium (estates), which were in the hands of a few economic and political elites.
=== SCD411: Aflibercept Biosimilar === SCD411 is a biosimilar referencing Regeneron and Bayer's Eylea, an anti-VEGF therapy indicated for neovascular age-related macular degeneration (wet AMD) and other retinal diseases. The drug completed global Phase 3 clinical trials in 2022 across 14 countries, involving 576 patients at 132 hospitals. SCD411 received regulatory approvals in Canada (June 2025), Europe (August 2025), South Korea, and Japan (both September 2025), in both vial and pre-filled syringe formats.
knots have been found to naturally occur in knotted molecules, they have not been successfully synthesized. Small-molecule composite knots have also not yet been synthesized. Artificial DNA, RNA, and protein knots have been successfully synthesized. DNA is a particularly useful model of synthetic knot synthesis, as the structure naturally forms interlocked structures and can be easily manipulated into forming knots control precisely the raveling necessary to form knots. Molecular knots are often synthesized with the help of crucial metal ion ligands.
Sources: en.wikipedia.org
Reversed-phase liquid chromatography with ultraviolet detection gives a purity estimate, while mass spectrometry confirms molecular mass and flags modifications. Amino acid analysis can add compositional confirmation. Results are most meaningful when a validated reference standard is run alongside the sample.
Cold, dry, and dark conditions are standard, typically at or below minus twenty degrees Celsius for long-term holding. Vials are usually warmed to room temperature before opening to prevent condensation. Repeated warming and cooling of the same vial is generally avoided.
This depends on pH, buffer, and concentration, with acidic conditions often reported as more favorable. Hydrolysis accelerates at room temperature, so solutions are commonly prepared fresh or stored frozen in single-use aliquots. No single shelf life applies across formulations.
The peptide is synthetic, but its sequence matches a segment of a protein present in human gastric juice. It does not occur as a free fifteen-residue peptide in the body.